The deal marks the largest M&A in South Korea's pharma and biotech industry, targeting the obesity drug market
Reliability 63 · high2 sources1 independent voice
rewrites detected
Todas las noticias sobre este tema, contrastadas en la prensa mundial — los hechos neutrales.